Tecentriq (atezolizumab)

pCPA File Number: 21167
Negotiation Status:
Active Negotiation
Indication(s):
For the treatment of the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance Tecentriq should be continued until loss of clinical benefit or unacceptable toxicity
Sponsor/Manufacturer:
Hoffmann-La Roche
CADTH Project Number:
PC0156-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable